Real-World Comparative Study of Atezolizumab-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer
These findings suggest that ABCP may offer superior efficacy in specific non-small cell lung cancer subgroups, while ACnP remains a valuable option for patients requiring a more tolerable safety profile.
Authors
- Hiroki Nakahara
- Ayaka Ohiwa
- Akihiko Yagi
- Hidenori Ibata
- Tadashi Sakaguchi (ORCID: https://orcid.org/0000-0003-1103-4276)
- Hisamichi Yuda
- Taro Yasuma
- Esteban C. Gabazza (ORCID: https://orcid.org/0000-0001-5748-1499)
- Tetsu Kobayashi (ORCID: https://orcid.org/0000-0003-4397-6137)
- T. Nishimura (ORCID: https://orcid.org/0000-0002-1688-1602)
- Shuji Kodama (ORCID: https://orcid.org/0000-0003-2883-0340)
- Aiko Ebihara
- Corina N. D’Alessandro‐Gabazza (ORCID: https://orcid.org/0000-0003-2164-5775)
- Taichi Isobe (ORCID: https://orcid.org/0000-0001-5686-1940)
- Takashi Hirai (ORCID: https://orcid.org/0000-0001-6200-0100)
- Atsushi Fujiwara (ORCID: https://orcid.org/0000-0002-7647-0733)
- Masamichi Yoshida
- Hajime Fujimoto (ORCID: https://orcid.org/0000-0002-4141-0538)
- Osamu Hataji
Institutions
- Suzuki (Japan) (JP)
- Mie University (JP)
- Mie Chuo Medical Center (JP)
- Sunagawa City Medical Center (JP)
- Soka Municipal Hospital (JP)
Publication Details
- Journal
- Cancers
- Published
- 2025-11-12
- DOI
- https://doi.org/10.3390/cancers17223630
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00